BioCardia gets positive PMDA consultation; next step after final CardiAMP HF data in Q1 2025

BioCardia, Inc.

Completed consultation with Japan PMDA; PMDA invited next consultation after submission of final 2-year follow-up data.
PMDA remains open to using CardiAMP Heart Failure Trial and prior trials for registration in Japan.
Company anticipates final data from 125-patient CardiAMP HF trial in Q1 2025.
BCDA-01 holds FDA Breakthrough Designation; U.S. trials supported by CMS reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.